Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC008-1A in recurrent CNS WHO grade 4 glioma
NCT06773481Phase 1Recruiting
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BC008-1A in glioblastoma (GBM) (2 arms), sponsored by Sichuan Luzhou Buchang Biopharmaceutical. Primary endpoint: Safety up to 2 years. Started Apr 2025; status: recruiting.
02
Drugs
BC008-1A
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06773481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773481.